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Purposes: Whether hepatectomy is justified in patients with hepatocellular carcinoma (HCC) on hemodialysis (HD) for end-
stage renal disease (ESRD) is unclear. This study evaluated clinical characteristics and outcomes in patients with HCC on HD
for ESRD who underwent hepatectomy.
Methods: Hepatectomy was performed in 17 patients in an ESRD group and 181 in a non-ESRD group. We compared clini-
cal characteristics and outcomes between these groups.
Results: Compared with the non-ESRD group, the ESRD group had a significantly higher rate of diabetes mellitus, higher
serum creatinine levels, lower levels of hemoglobin, aspartate aminotransferase, and alanine aminotransferase, and a lower
indocyanine green retention rate at 15 min. There were no significant differences between the 2 groups in other clinical char-
acteristics, laboratory data, surgical outcomes, pathological findings, or overall postoperative morbidity or mortality. How-
ever, the incidence of postoperative pneumonia, gastrointestinal bleeding, and intra-abdominal bleeding was significantly
higher in the ESRD group. The 5-year disease-free survival rate was 44.3% in the ESRD group and 24.0% in the non-ESRD
group (p=0.4483), and the 5-year survival rates were 76.4% and 65.1% (p=0.2291), respectively. HD and serum creatinine
levels were not significant prognostic factors for survival and recurrence.
Conclusion: Hepatectomy for HCC in patients with ESRD on HD may be associated with increased risk of postoperative
pneumonia, gastrointestinal bleeding, and intra-abdominal bleeding, but is feasible if careful surgical and perioperative man-
agement are provided.
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Introduction
Hepatectomy has been recognized as one of the most ef-
fective treatments for patients with hepatocellular carci-
noma (HCC) and has become a safe operation with a
relatively low mortality rate.
１-４
Patients with end-stage re-
nal disease (ESRD) on hemodialysis (HD) have a higher
incidence of viral hepatitis infection and HCC than the
general population, and HCC is a significant risk factor
for morbidity and mortality in patients who are receiving
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HD.
５-７
In addition, the risk of malignant disease is higher
in patients with ESRD than in those without ESRD.
８
Ma-
jor surgery can now be performed in patients with ESRD
because of recent advances in surgical techniques and pe-
rioperative management.
９-１２
Several authors have reported
morbidity rates of 5% to 36% and mortality rates of 0%
to 10% in dialysis patients who underwent elective ab-
dominal surgery,
９-１２
but hepatectomy for HCC in patients
with ESRD remains risky due to various serious compli-
cations. Few studies have evaluated hepatectomy for
HCC in patients with ESRD on HD.
１３-１６
The aim of this
retrospective study was to evaluate the clinical character-
istics and short- and long-term outcomes of hepatectomy
for HCC in patients with ESRD on HD.
Materials and Methods
This study was approved by the Institutional Ethics Re-
view Board at the Tokyo Women’s Medical University
(No. 5158) and conducted in accordance with the princi-
ples invoked in the Helsinki Declaration. Between Janu-
ary 1998 and December 2010, 17 patients with ESRD on
HD underwent initial curative hepatectomy for HCC
(ESRD group) at the Department of Surgery, Institute of
Gastroenterology, Tokyo Women’s Medical University
Hospital, while 181 patients without ESRD underwent
initial curative hepatectomy for HCC (non-ESRD group).
We compared the clinical characteristics and the short-
and long-term hepatectomy outcomes between the 2
groups. The indications for hepatectomy and the surgical
procedures were determined according to tumor size,
number, and type; liver function including indocyanine
green retention rate at 15 min (ICGR15); and the allow-
able extent of hepatic resection, evaluated using a loga-
rithmic graph based on the ICGR15.
１７-１８
The criteria for he-
patectomy and the surgical procedure did not differ sig-
nificantly between the ESRD and non-ESRD groups. The
terminology used to describe the anatomic characteristics
of the liver and resection were in accordance with the
recommendations of the Terminology Committee of the
International Hepato-Pancreato-Biliary Association in
2000.
１９
Patients with simple nodular HCC without satel-
lite nodules with a diameter of3 cm underwent segmen-
tectomy, subsegmentectomy, or limited resection. Pa-
tients with large, simple nodular HCC and satellite nod-
ules underwent sectionectomy or hemihepatectomy. Ma-
jor hepatectomy was defined as the resection of 2 or
more segments, while minor hepatectomy was defined as
the resection of fewer than 2 segments, including limited
resection. Curative resection was defined as complete tu-
mor removal, with negative macroscopic and micro-
scopic findings. Hepatectomy with Glissonean pedicle
transection at the hepatic hilum was usually per-
formed.
２０-２２
Liver parenchymal transection was performed
using a Cavitron Ultrasonic Surgical Aspirator (CUSA
System, Valleylab Inc, Boulder, CO, USA) during an in-
termittent Pringle maneuver with 10-15 min of inflow
occlusion and 5 min of reperfusion.
Protocol for perioperative management of HD
All patients regularly received HD 3 times per week,
with nafamostat mesilate within 24 h before the opera-
tion. The first postoperative HD session was performed
on postoperative day 2, using nafamostat mesilate. The
second postoperative session of HD was performed on
postoperative day 4 using conventional methods, with
addition of heparin if the patient was free of events.
Clinical characteristics
The following clinical characteristics were recorded
and analyzed: age, sex, hepatitis B surface antigen (HBs-
Ag), hepatitis C virus antibody (HCV-Ab), presence or
absence of diabetes mellitus, laboratory data including
complete blood count (hemoglobin, platelet count), re-
sults of biochemical analyses including total bilirubin (T-
bil), albumin (Alb), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), prothrombin time (PT),
creatinine, and ICGR15, tumor marker ( serum α-
fetoprotein), Child-Pugh grade, liver cirrhosis, tumor size
and number, and intra- and postoperative factors includ-
ing surgical procedure, operative time, blood loss, in-
traoperative blood transfusion, morbidity, mortality, and
duration of hospital stay (days) after hepatectomy. Patho-
logical factors including macroscopic tumor type, histo-
logical grade, vascular invasion, and intrahepatic metas-
tasis were evaluated according to the General Rules for
the Clinical and Pathological Study of Primary Liver
Cancer, issued by the Liver Cancer Study Group of Ja-
pan.
２３
Survival duration was defined as the time from
liver surgery to the date of death or last contact. The me-
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Table　1　Background characteristics of patients with HCC who 
underwent hepatectomy in the ESRD and non-ESRD groups.
ESRD 
(n=17)
non-ESRD 
(n=181)
p-value
Age (years) 66.0 (41-79) 67.0 (16-83) 0.757
Sex (male/female) 15/2 144/37 0.390
HBs-Ag (+)  2 (11.8%)  29 (16.0%) 0.459
HCV-Ab (+) 10 (58.8%)  95 (52.5%) 0.617
Liver cirrhosis (+)  5 (29.4%)  74 (40.9%) 0.356
Child-Pugh grade (A/B/C) 14/3/0 155/23/3 0.745
A 14 (82.4%) 155 (85.7%) 0.714
Diabetes mellitus (+)  9 (52.9%)  41 (22.7%) <0.0001
HCC, hepatocellular carcinoma; ESRD, end-stage renal disease; non-
ESRD, non-end-stage renal disease; HBs-Ag, hepatitis B surface an-
tigen; HCV-Ab, hepatitis C virus antibody.
Table　2　Laboratory data of patients with HCC who underwent 
hepatectomy in the ESRD and non-ESRD groups.
ESRD 
(n=17)
non-ESRD 
(n=181)
p-value
T-bil (mg/dl) 0.3 (0.1-0.6) 0.6 (0.2-27.7) 0.311
Alb (g/dl) 3.8 (2.9-4.3) 3.8 (2.4-4.9) 0.702
AST (IU/L) 20 (7-60) 49 (12-214) <0.0001
ALT (IU/L) 18 (5-50) 44 (11-232) <0.0001
PT (%) 95.3 (63-100) 86.8 (45-100) 0.179
Plt (×104/μL) 14.8 (8.2-31.2) 13.2 (3.7-41) 0.256
Hb (g/dl) 10.0 (8.7-12.9) 13.3 (9.0-16.3) <0.0001
Cre (mg/dl) 9.69 (6.18-15.79) 0.77 (0.39-2.49) <0.0001
ICGR15 (%) 11.0 (1-23) 15.0 (3-71) 0.037
AFP (ng/ml) 5.0 (1-2,630) 26 (1-1,625,800) 0.708
HCC, hepatocellular carcinoma; ESRD, end-stage renal disease; non-
ESRD, non-end-stage renal disease; T-bil, total bilirubin; Alb, albu-
min; AST, aspartate aminotransferase; ALT, alanine aminotransfer-
ase; PT, prothrombin time; Plt, platelet count; Hb, hemoglobin; Cre, 
creatinine; ICGR15, indocyanine green retention rate at 15 minutes; 
AFP, α-fetoprotein.
dian follow-up was 22 months (range, 5-86 months).
Statistical analysis
Data are presented as percentages or medians with
ranges. The Mann-Whitney U test and Fisher’s exact test
were used to compare intergroup differences. The overall
and disease-free survival rates were calculated with the
Kaplan-Meier method, while survival rates were com-
pared using the log-rank test. The potential predictors of
survival and disease-free survival were evaluated using a
multivariate analysis, Cox proportional hazards model. P
values <0.05 were considered to indicate statistical sig-
nificance. All statistical analyses were performed using
the JMP 14 statistical software package (SAS Institute
Inc., Cary, NC, USA).
Results
Comparison of background characteristics and
laboratory data
The background characteristics of patients with HCC
who underwent hepatectomy in the ESRD and non-
ESRD groups are shown in Table 1. The ESRD group
comprised 15 men and 2 women, with a median age of
66 years (range, 41-79). All patients in this group re-
ceived HD for ESRD. The causes of ESRD were diabetic
nephropathy in 9 patients, nephrotic syndrome in 3, im-
munoglobulin A nephropathy in 3, sclerotic kidney syn-
drome in 1, and unknown in 1. The median HD duration
was 48 months (range, 1-291). In the ESRD group, mark-
ers for hepatitis were positive in 12 patients (70.6%;
HCV-Ab positive in 10, HBs-Ag positive in 2). A signifi-
cantly higher proportion of patients in the ESRD group
than in the non-ESRD group had diabetes mellitus. There
were no cases with cardiac dysfunction in the ESRD
group. Other background characteristics did not differ
significantly between the 2 groups. The laboratory data
of patients in the ESRD and non-ESRD groups are
shown in Table 2. The ESRD group had a significantly
higher mean serum creatinine level and significantly
lower hemoglobin, serum AST, serum ALT, and ICGR15
levels than the non- ESRD group. There were no signifi-
cant intergroup differences in any other laboratory vari-
ables.
Comparison of surgical outcomes and pathological
findings
The surgical outcomes in the ESRD and non-ESRD
groups are shown in Table 3. There were no significant
intergroup differences in surgical procedure, operative
time, operative blood loss, or intraoperative blood trans-
fusion. The pathological findings in the ESRD and non-
ESRD groups are shown in Table 4. Tumor size, tumor
number, macroscopic tumor type, histological grade, vas-
cular invasion, and intrahepatic metastasis were similar
between the groups.
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Table　3　Surgical outcomes in patients with HCC who underwent hepatectomy in the 
ESRD and non-ESRD groups.
ESRD (n=17) non-ESRD (n=181) p-value
Surgical procedure
Major hepatectomy  13 (76.5%) 111 (61.3%) 0.217
Minor hepatectomy   4 (23.5%)  70 (38.7%) 0.202
Sectionectomy or larger resection   7 (41.2%)  83 (45.9%) 0.711
Operative time (min)  190 (140-300)  203 (74-760) 0.329
Blood loss (ml)    780 (130-1,690)   880 (6-9,300) 0.294
Blood transfusion (n) 7 (41%)  55 (30.4%) 0.359
HCC, hepatocellular carcinoma; ESRD, end-stage renal disease; non-ESRD, non-end-stage 
renal disease.
Table　4　Pathological findings in patients with HCC who underwent hepatectomy in the 
ESRD and non-ESRD groups.
ESRD (n=17) non-ESRD (n=181) p-value
Tumor size (cm) 4.5 (1.3-9.8) 5.0 (1-19) 0.781
Solitary tumor 14 (82%)  126 (69.6%) 0.270
Macroscopic tumor type simple nodular 10 (59%)   78 (43.1%) 0.212
Histological grade
well/moderate/poor 1/15/1 12/156/13 0.814
moderate 15 (88%)  156 (86.2%)
Vascular invasion  3 (18%) 47 (26%) 0.335
Intrahepatic metastasis   1 (5.9%)   30 (16.6%) 0.217
HCC, hepatocellular carcinoma; ESRD, end-stage renal disease; non-ESRD, non-end-stage re-
nal disease; well, well-differentiated adenocarcinoma; moderate, moderately-differentiated ade-
nocarcinoma; poor, poorly-differentiated adenocarcinoma.
Table　5　Postoperative morbidity and mortality in patients with 
HCC who underwent hepatectomy in the ESRD and non-ESRD
groups.
ESRD 
(n=17)
non-ESRD 
(n=181)
p-value
Morbidity 7 (41.2%) 59 (32.6%) 0.473
Ascites or pleural effusion 2 (11.8%) 27 (14.9%) 0.532
Bile leakage 0 21 (11.6%) 0.136
Intra-abdominal abscess 0 6 (3.3%) 0.579
Prolonged jaundice 0 5 (2.8%) 0.635
Pneumonia 2 (11.8%) 3 (1.7%) 0.011
Gastrointestinal bleeding 1 (5.9%) 1 (0.6%) 0.036
Intra-abdominal bleeding 1 (5.9%) 1 (0.6%) 0.036
Shunt infection, obstruction 1 (5.9%)
Hospital stay (days) 15 (11-69) 15 (7-83) 0.337
Mortality 0 6 (3.3%) 0.446
HCC, hepatocellular carcinoma; ESRD, end-stage renal disease; non-
ESRD, non-end-stage renal disease.
Comparison of postoperative morbidity and mor-
tality
Postoperative morbidity and mortality rates in the
ESRD and non-ESRD groups are shown in Table 5. In
the ESRD group, postoperative morbidity was observed
in 7 patients (41.2%), with massive ascites or pleural ef-
fusion in 2 (11.8%), pneumonia in 2 (11.8%), gastroin-
testinal bleeding from duodenal ulcer in 1 (5.9%), shunt
infection and obstruction in 1 ( 5.9% ) , and intra-
abdominal bleeding in 1 (5.9%); no surgical site infection
was observed, including intra-abdominal abscess and
sepsis. Although overall morbidity rates did not differ
significantly between the 2 groups (41.2% vs. 32.6%; p=
0.473), the ESRD group had significantly higher rates of
pneumonia (11.8% vs. 1.7%; p=0.011), gastrointestinal
bleeding (5.9% vs. 0.6%; p=0.036), and intra-abdominal
bleeding (5.9% vs. 0.6%; p=0.036) than the non-ESRD
group. One case had intra-abdominal bleeding from the
cut surface of the liver on postoperative day 1, requiring
hemostasis at relaparotomy. This case was considered a
surgery-related complication. Only the development of
shunt infection and obstruction in 1 case was considered
a postoperative HD-related complication. There were no
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Figure　1　Overall survival after hepatectomy for HCC in the 
ESRD and non-ESRD groups (p=0.2291).
HCC, hepatocellular carcinoma; ESRD group, patients with end-
stage renal disease; non-ESRD group, patients without end-stage 
renal disease.
Figure　2　Disease-free survival after hepatectomy for HCC in
the ESRD and non-ESRD groups (p=0.4483).
HCC, hepatocellular carcinoma; ESRD group, patients with end-
stage renal disease; non-ESRD group, patients without end-stage 
renal disease.
cases of in-hospital mortality in the ESRD group. The
median postoperative hospital stay was 15 days (range,
11-69 days) in the ESRD group. Postoperative mortality
and length of hospital stay (days) did not differ signifi-
cantly between the 2 groups.
Comparison of overall survival and disease-free
survival rates
Overall survival and disease-free survival rates are
shown in Figure 1, 2. The overall survival rates at 1, 3,
and 5 years were 100%, 91.7%, and 76.4% in the ESRD
group and 88.9%, 75.6%, and 65.1% in the non-ESRD
group, respectively. The disease-free survival rates at 1,
3, and 5 years were 64.6%, 44.3%, and 44.3% in the
ESRD group and 75.4%, 38.6%, and 24.0% in the non-
ESRD group, respectively. There were no significant in-
tergroup differences in overall or disease-free survival
rates.
Prognostic factors for survival and recurrence in
univariate and multivariate analyses
In univariate analysis, serum Alb level <3.5 (p=0.005),
prothrombin time <80 (p=0.002), platelet count <10 ×
10
4
(p=0.001), and serum alpha-fetoprotein level100 (p
=0.009) were significant prognostic factors for overall
survival (Table 6). In multivariate analysis, these were
not significant. In univariate analysis, platelet count <10
× 104 (p=0.005) was a significant prognostic factor for
disease-free survival. In multivariate analysis, it was not
significant (Table 7 ) . HD and serum creatinine level
were not significant prognostic factors for survival and
recurrence.
Discussion
This study was performed to evaluate the clinical charac-
teristics and short- and long-term outcomes of hepatec-
tomy for HCC in patients with ESRD on HD. We com-
pared the long-term outcomes of hepatectomy for HCC
in patients with and without ESRD. Overall or disease-
free survival rates did not differ between the ESRD and
non-ESRD groups. HD and the serum creatinine level
were not significant prognostic factors for survival and
recurrence. However, the incidence of postoperative
pneumonia, gastrointestinal bleeding, and intra-
abdominal bleeding was significantly higher in the ESRD
group. Our findings suggest that hepatectomy for HCC is
feasible in patients with ESRD on HD, provided that
careful surgical and perioperative management for pneu-
monia and bleeding is performed.
The Renal Data Registry Committee of the Japanese
Society for Dialysis Therapy reported that causes of
death in patients with ESRD include infectious diseases
(26.5%), cardiac failure (24.9%), and malignant tumors
(12.5%).
２４
ESRD has also been associated with increased
risk of surgical complications, including infection, elec-
trolyte disturbances, fluid overload, cardiac failure, ane-
mia, and bleeding tendency. More patients with ESRD
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Table　6　Univariate and multivariate analyses of prognostic factors for overall survival.
Variable
Univariate Multivariate
p-value Odds ratio (95% CI) p-value
Age (years) <70 vs ≥70 0.051
Sex male vs female 0.310
HBs-Ag positive vs negative 0.191
HCV-Ab positive vs negative 0.794
Liver cirrhosis present vs absent 0.238
Diabetes mellitus present vs absent 0.256
HD present vs absent 0.229
Alb (g/dl) <3.5 vs ≥3.5 0.005 1.136 (0.599-2.104) 0.689
ALT (IU/L) <50 vs ≥50 0.502
PT (%) <80 vs ≥80 0.002 1.363 (0.730-2.519) 0.327
Plt (×104/μL) <10 vs ≥10 0.001 1.467 (0.787-2.717) 0.226
Hb (g/dl) <10 vs ≥10 0.633
Cre (mg/dl) <2.0 vs ≥2.0 0.408
ICGR15 (%) <20 vs ≥20 0.515
AFP (ng/ml) <100 vs ≥100 0.009 1.711 (0.991-2.916) 0.053
Major hepatectomy present vs absent 0.606
Blood loss (ml) <1,000 vs ≥1,000 0.172
Tumor size (cm) <3 vs ≥3 0.778
Histological grade moderate present vs absent 0.807
Vascular invasion present vs absent 0.163
Intrahepatic metastasis present vs absent 0.624
HD, hemodialysis.
Table　7　Univariate and multivariate analyses of prognostic factors for disease-free survival.
Variable
Univariate Multivariate
p-value Odds ratio (95% CI) p-value
Age (years) <70 vs ≥70 0.866
Gender male vs female 0.897
HBs-Ag positive vs negative 0.986
HCV-Ab positive vs negative 0.412
Liver cirrhosis present vs absent 0.892
Diabetes mellitus present vs absent 0.941
HD present vs absent 0.449
Alb (g/dl) <3.5 vs ≥3.5 0.130
ALT (IU/L) <50 vs ≥50 0.963
PT (%) <80 vs ≥80 0.136
Plt (×104/μL) <10 vs ≥10 0.005 1.478 (0.942-2.282) 0.088
Hb (g/dl) <10 vs ≥10 0.249
Cre (mg/dl) <2.0 vs ≥2.0 0.616
ICGR15 (%) <20 vs ≥20 0.584
AFP (ng/ml) <100 vs ≥100 0.378
Major hepatectomy present vs absent 0.967
Blood loss (ml) <1,000 vs ≥1,000 0.929
Tumor size (cm) <3 vs ≥3 0.709
Histological grade moderate present vs absent 0.785
Vascular invasion present vs absent 0.071
Intrahepatic metastasis present vs absent 0.630
HD, hemodialysis.
are thus likely to require surgical treatment. Hepatectomy
was therefore considered to be contraindicated in such
patients. Kaibori et al.
２５
evaluated 57 HCC patients with
renal dysfunction, of whom only 5 were on HD, and
found that postoperative morbidity rates did not differ be-
tween those with and without renal dysfunction after he-
―40―
patectomy. In contrast, Toshima et al.
２６
evaluated 17
HCC cases with renal dysfunction (defined as serum cre-
atinine >2.0 mg/dl), and reported that these patients had a
significantly higher risk of postoperative massive ascites
and pleural effusion than those without renal dysfunction
after hepatectomy. However, these reports included only
small numbers of patients on HD. There are only a few
reports on hepatectomy for HCC in patients with ESRD
on HD.
１３-１６
Yeh et al.
１４
reported a morbidity rate of 42.3% and a
mortality rate of 11.5% in 26 patients with ESRD who
received hepatectomy for HCC. The postoperative mor-
bidity rate was significantly higher than in patients with-
out ESRD, with a higher risk of postoperative massive
ascites and pleural effusion, but the postoperative mortal-
ity rate did not differ significantly. Orii et al.
１５
reported a
morbidity rate of 58.8% and a mortality rate of 0% in 17
patients with ESRD who underwent hepatectomy for
HCC. There were no significant differences in overall
postoperative morbidity or mortality as compared with
patients without ESRD. Only the incidence of circulatory
insufficiency was higher in patients with ESRD. Yeh et
al.
１６
reported that patients with ESRD did not show an in-
crease in overall postoperative complications, but did
have a significantly higher risk of infection and heart-
associated complications. These studies reported in-
creased morbidity rates in patients with ESRD who un-
derwent hepatectomy for HCC, but no significant differ-
ences in postoperative mortality were confirmed. In our
study, overall postoperative morbidity rates ( ESRD :
41.2% vs. non-ESRD: 32.6%; p=0.473) and mortality
rates (ESRD: 0% vs. non-ESRD: 3.3%; p=0.446) did not
differ significantly between the 2 groups. The results of
our study were similar to those of previous studies.
Postoperative pneumonia occurred in 2 patients
(11.8%) in our study. Drolet et al.
２７
evaluated 5,806 pa-
tients on HD who underwent colorectal surgery, and
found that the rates of pulmonary (23%) and infectious
(25%) complications after colorectal resection were sig-
nificantly higher in those with ESRD. Some studies re-
ported that dialysis treatment induces hypoxemia because
of carbon dioxide diffusion through the dialysate, subse-
quently leading to hypocapnia and hypoventilation.
These events may lead to a higher risk of developing
atelectasis and pneumonia.
２８，２９
Although there were no
significant intergroup differences in platelet count and
prothrombin time in our data, postoperative gastrointesti-
nal bleeding (5.9%) and intra-abdominal bleeding (5.9%)
rates were significantly higher in patients with ESRD.
Patients with ESRD demonstrate coagulation abnormali-
ties related to platelet dysfunction that lead to bleeding
complications.
３０
Therefore, the use of anticoagulants dur-
ing HD sessions after hepatectomy should be monitored
carefully. Hepatectomy is characterized by large fluid
shifts in the perioperative period. Patients with ESRD are
not able to correct for large volume shifts and hemody-
namic changes associated with HD treatments. These
lead to complications related to fluid overload, circula-
tory insufficiency, and cardiac failure. Orii et al.
１５
re-
ported that the incidence of circulatory insufficiency was
higher in patients with ESRD. Yeh et al.
１６
reported a sig-
nificantly higher risk of heart-associated complications in
patients with ESRD. Our study observed no episodes of
circulatory insufficiency or cardiac failure and no signifi-
cant differences in postoperative massive ascites and
pleural effusion. Although the presence of hepatitis viral
markers, liver cirrhosis, and Child-Pugh grade showed no
significant intergroup differences, the ESRD group had
significantly lower ICGR15 levels than the non-ESRD
group, possibly because our study selected patients with
good liver function. Patients with ESRD have impaired
immune function, characterized by induction of a proin-
flammatory state, and decreased number and function of
lymphoid and phagocytic cells,
３１，３２
leading to complica-
tions related to surgical site infection and sepsis. Al-
though the criteria for hepatectomy and the surgical pro-
cedure did not differ significantly between the ESRD and
non-ESRD groups, there were no episodes of surgical
site infection in our study, including intra-abdominal ab-
scess and sepsis.
Most authors
１３-１５，２６
reported that the 5-year survival and
disease-free survival rates showed no significant differ-
ences between ESRD and non-ESRD groups. However,
Orii et al.
１５
reported that the 5-year survival and disease-
free survival rates, respectively, were 55.3% and 36.1%
in the ESRD group and 66.0% and 30.1% in the non-
ESRD group. The disease-free survival rate did not differ
significantly between the groups, but the overall survival
rate was significantly lower in the ESRD group than in
the non-ESRD group. The survival time after recurrence
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was significantly shorter in the ESRD group than the in
the non-ESRD group. Some authors have reported that
rapid tumor progression might be caused by immunosup-
pression in patients with HCC who have ESRD.
１５，３３
The
incidence of malignant disease is higher in patients with
ESRD than in the non-ESRD population.
８
Because cellu-
lar and humoral immune responses are suppressed in pa-
tients with ESRD,
３４，３５
the risk of recurrence of HCC may
also be increased by immunosuppression in patients with
ESRD. Some authors have reported that elevated serum
blood urea nitrogen, serum creatinine, and creatinine
clearance <70 mg/min were risk factors associated with
poor outcomes in patients with ESRD who underwent
hepatectomy for HCC.
１４，２５
However, there were no sig-
nificant intergroup differences in overall or disease-free
survival rates, and HD and serum creatinine levels were
not significant risk factors for survival and recurrence in
our study. Some authors have reported that liver function
parameters included serum Alb level <3.5, platelet count
<8× 104, prolonged prothrombin time-international nor-
malized ratio ( PT-INR ) > 1.10, and serum alpha-
fetoprotein level were risk factors associated with poor
outcomes in patients who underwent hepatectomy for
HCC.
３，４，３６
The results of our study in univariate analysis
were similar to those of studies. However, these were not
significant risk factors in multivariate analysis, possibly
because our study selected small number of patients.
This study had several limitations. This was a retro-
spective, single-center study of a relatively small number
of patients with ESRD on HD. The patients in this study
who underwent hepatectomy represent a narrowly se-
lected group. However, hepatectomy for HCC should not
be a contraindication in patients with ESRD.
Conclusion
Hepatectomy for HCC in patients with ESRD on HD
may be associated with an increased risk for development
of postoperative pneumonia, gastrointestinal bleeding,
and intra-abdominal bleeding, but is feasible provided
that careful surgical and perioperative management is
provided. However, further investigation is needed to
confirm the validity of our findings.
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